Study design and patient selection
SQUAMOUS CELL CARCINOMA, BRAIN METASTASES, ONCOLOGY, RECURRENT NSCLC, INTERSTITIAL LUNG DISEASE
This multi‐institutional phase II trial employed a single‐arm, prospective, and open‐label design. The study protocol has been previously reported and registered in the Japan Registry of Clinical Trials (jRCTs071190015, Figure The key eligibility criteria were as follows: patients with advanced or recurrent NSCLC excluding squamous cell carcinoma, harboring EGFR‐activating mutations, aged ≥20 years, a performance status (PS) of ≤2 based on the Eastern Cooperative Oncology Group scale, and adequate organ function. The main exclusion criteria were symptomatic brain metastases and interstitial lung disease.